Adlai Nortye, a China-based clinical-stage biopharmaceutical firm that develops immuno-oncology medicines, on Monday announced the completion of nearly $100 million in a Series C round of financing.
The Series C round was co-led by Hong Kong-listed clinical trial and research firm Hangzhou Tigermed Consulting and Shanghai-based asset manager Yingke PE. Other investors included ATCG Holdings; ICBC Asset Management (Global) Company Limited, the overseas investment management arm of China’s ICBC Group; and several funds affiliated with Yingke PE.
